Yes Ashley moving forward with his plan and articulating it well for all to see.... Here is the most recent release....profitable and growing company reverse merging into RSHN.
Chattahoochee Labs/heliosDx Corporate Update, Acquisition and Roadmap Tuesday, May 18, 2021 9:00 AM Share this article now Topic: Company Update ALPHARETTA, GA / ACCESSWIRE / May 18, 2021 / RushNet, Inc (OTC PINK:RSHN), ("the Company") recently acquired Chattahoochee Labs/heliosDX, announced via twitter the temporary withdrawal of their FINRA application for the name change, symbol change, and R/S. To get RushNet, Inc Pink current, we needed to have no pending corporate actions. Additionally, we filed with the Colorado SOS to revert to RushNet, Inc from heliosDX as per the OTCMarkets. Now we can move forward with completing necessary actions to become Pink current.
Also released via Twitter, we have finalized discussions to acquire a privately held laboratory with substantial revenues to join heliosDX. The proposed newly acquired laboratory would triple our revenues and quadruple our throughput. Once the Binding LOI is executed, additional information will be made available. This is the first major step of many in regards to positioning heliosDX as a presence on the national stage. As any major transaction, we cannot guarantee the outcome, but only the validity in nature as it stands today.
Below is the roadmap of key events to expect in the near term. We cannot guarantee these events will happen in this order. Some events are outside the control of the company, and cannot occur until previous events are completed.
Filing Disclosures Filing Financials Attorney Letter Mid Quarter Financial update and Highlights Pink Current Acquisition(s) and/or LOI Update R/S Reassessment Reengage FINRA SEC Reporting As always, we will continue to use Twitter as a source for keeping our shareholders and the investment community updated with company activities, and PR material events when necessary. You can view our Twitter by visiting https://twitter.com/dx_helios.
About heliosDX and Chattahoochee Labs:
Having begun operations in 2015, the company has witnessed profit and exceptional growth each year and is predicting well over 6 million dollars in revenue in 2021. This year we take on our third mass spectrometer, the powerful Absciex 4500, which will allow us to serve the massive needs of our clientele, which has been under strain. With the procurement of a new QuantStudio 12x we now have the ability to test 1500 Covid19 patients per day. With infectious disease testing validations being completed next week, we will be able to better serve clients all over by creating more robust testing menus and quicker turnaround time for Covid19, UTI, and RPP testing. Furthermore, with the assumption of our Ion S5 GeneStudio NGS testing equipment, we are poised for the huge genetics market that is so underserved. The company is currently in the midst of rebranding from Chattahoochee Labs to heliosDX.
News 
Market Data 
Discover 
